Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 6/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.34 |
| ▸ | WNT3A | P56704 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20480472 | 0.90 | KDM4E (0.41) | KDM4ELMNAALDH1A1HSD17B10PTGDR2 | |
| SCHEMBL20480596 | 0.89 | ALDH1A1 (0.37) | KDM4ELMNAALDH1A1HSD17B10PTGDR2 | |
| SCHEMBL20480628 | 0.89 | PTGDR2 (0.38) | KDM4ELMNAALDH1A1HSD17B10PTGDR2 | |
| SCHEMBL20480619 | 0.82 | CYP1A2 (0.45) | KDM4ELMNAALDH1A1HSD17B10PTGDR2 | |
| SCHEMBL20480552 | 0.80 | HTR2A (0.35) | ALDH1A1PTGDR2HTR1AMEN1KMT2A | |
| SCHEMBL20480421 | 0.80 | PTGDR2 (0.35) | ALDH1A1HSD17B10PTGDR2MEN1KMT2A | |
| SCHEMBL20478663 | 0.78 | CYP1A2 (0.41) | KDM4ELMNAPTGDR2MEN1KMT2A | |
| SCHEMBL20480545 | 0.78 | PTGDR2 (0.45) | PTGDR2HTR1ACTNNB1WNT3A | |
| SCHEMBL20478615 | 0.76 | PTGDR2 (0.40) | PTGDR2MEN1KMT2A | |
| SCHEMBL20480598 | 0.76 | HTR1A (0.35) | KDM4ELMNAALDH1A1HSD17B10HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10428017-B2 | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use | ABBVIE S.Á.R.L. (LU) | 2019-10-01 | — | — | US | disclosed |
| WO-2018154493-A1 | MODULATORS OF THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR PROTEIN AND METHODS OF USE | AbbVie S.à.r.l. (LU) | 2018-08-30 | — | — | WO | disclosed |
| US-20180244640-A1 | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | ABBVIE S.Á.R.L. (LU) | 2018-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428017-B2 | Modulators of the cystic fibrosis transmembrane conductance regulator protein and methods of use | CFTR, CLCN2, SCNN1G | KDM4E 4044/4885LMNA 3733/4885ALDH1A1 4131/4885 |
| US-20180244640-A1 | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | CFTR, CLCN2, SCNN1G | KDM4E 4044/4885LMNA 3733/4885ALDH1A1 4131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.